medicina57巻10号

2020年09月発行

特集 循環器診療2020—どこまで攻めて，どこから引くか？ 画像診断・その他

MRIを用いた心筋症の鑑別

著者： 加藤真吾¹

所属機関： ¹横浜市立大学大学院医学研究科放射線診断学教室

ページ範囲：P.1746 - P.1750

Point
◎遅延造影MRIは，虚血性心筋症と非虚血性心筋症の鑑別に役立つ．
◎拡張型心筋症においてβ遮断薬などの薬物治療の効果予測ができる．
◎薬物負荷心筋血流MRIは虚血を正確に評価できる．
◎MRIは肥大型心筋症や心サルコイドーシスの診断やリスク評価に役立つ．
◎T1マッピングは，心アミロイドーシスや心Fabry病の鑑別に有用である．

参考文献

1）Mahrholdt H, et al：Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26：1461-1474, 2005

2）Di Marco A, et al：Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy；Systematic review and meta-analysis. JACC Heart Fail 5：28-38, 2017

3）Masci PG, et al：Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy；A contrast-enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging 6：790-799, 2013

4）Bogun FM, et al：Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy；Utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol 53：1138-1145, 2009

5）Chalil S, et al：Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace 9：1031-1037, 2007

6）Kim RJ, et al：The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343：1445-1453, 2000

7）Greenwood JP, et al：Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease（CE-MARC）；A prospective trial. Lancet 379：453-460, 2012

8）Danad I, et al：Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard；A meta-analysis. Eur Heart J 38：991-998, 2017

9）Greenwood JP, et al：Prognostic value of cardiovascular magnetic resonance and single-photon emission computed tomography in suspected coronary heart disease；Long-term follow-up of a prospective, diagnostic accuracy cohort study. Ann Intern Med 165：1-9, 2016.

10）Kato S, et al：Stress perfusion coronary flow reserve versus cardiac magnetic resonance for known or suspected CAD. J Am Coll Cardiol 70：869-879, 2017

11）Nagel E, et al：Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med 380：2418-2428, 2019

12）Satoh H, et al：Delayed enhancement on cardiac magnetic resonance and clinical, morphological, and electrocardiographical features in hypertrophic cardiomyopathy. J Card Fail 15：419-427, 2009

13）Chan RH, et al：Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130：484-495, 2014

14）Okasha O, et al：Myocardial involvement in patients with histologically diagnosed cardiac sarcoidosis；A systematic review and meta-analysis of gross pathological images from autopsy or cardiac transplantation cases. J Am Heart Assoc 8：e011253, 2019

15）Miyazaki S, et al：Cardiac sarcoidosis complicated with atrioventricular block and wall thinning, edema and fibrosis in left ventricle；Confirmed recovery to normal sinus rhythm and visualization of edema improvement by administration of predonisolone. Int J Cardiol 150：e4-10, 2011

16）Kandolin R, et al：Diagnosing isolated cardiac sarcoidosis. J Intern Med 270：461-468, 2011

17）Fontana M, et al：Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132：1570-1579, 2015

18）Maurer MS, et al：Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379：1007-1016, 2018

19）Gillmore JD, et al：Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133：2404-2412, 2016

20）Haaf P, et al：Cardiac T1 mapping and extracellular volume（ECV）in clinical practice；A comprehensive review. J Cardiovasc Magn Reson 18：89, 2016